On February 15, 2024 TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, reported that CEO, Bryan Kobel and Process Development Manager, Dr. Lauren Bor will be featured "Expert Speakers" at the 7th 7th CAR-TCR Summit Europe, February 27-29th in London, UK (Press release, TC Biopharm, FEB 15, 2024, View Source [SID1234640163]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cell therapy industry experts will unite in for the only cell therapy conference looking in-depth at boosting clinical durability, advancing predictive biomarkers, and implementing safety switches through to automating production and accelerating analytical processes to reduce operational costs and turnaround times; and new cell therapy technology.

The 7th CAR-TCR Summit Europe provides exclusive access to the most cutting-edge advances across pre-clinical platforms, clinical advances, and streamlined manufacturing. The summit is your must-attend forum to stay at the forefront of cell therapy innovations. For more information or to register click here; View Source